Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

Net proceeds are intended to advance MICVO through clinical milestones, including the planned Headliner Phase 3 trial.

Rhea-AI Summary

Pyxis Oncology (PYXS) closed its public offering on October 1, 2026, raising approximately $110.0 million in upfront gross proceeds. It issued 36,047,919 common shares at $2.90 each and pre-funded warrants for 1,883,121 shares at $2.899 each, accompanied by common warrants for 49,310,352 shares.

The common warrants have a $3.50 exercise price and require an effective, stockholder-approved increase in authorized shares. Full cash exercise would bring total gross proceeds to approximately $282.6 million, before applicable expenses. Their expiration is linked to disclosure of MICVO Phase 1 overall survival data, expected in the first half of 2027. Pyxis intends to fund MICVO development, including the planned Headliner Phase 3 trial, and plans combination-study data in the fourth quarter of 2026.

5 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 6 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointApproximately $110.0 million in upfront gross proceeds raised through the completed offering. 60% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Approximately $172.6 million in additional gross proceeds possible if all milestone-linked common warrants are exercised for cash.
• Minor point. Forward-looking: it has not happened yet and may not happen.MICVO development is the intended use of net proceeds, including the planned Headliner Phase 3 trial.
• Minor point. Forward-looking: it has not happened yet and may not happen.Phase 1 overall survival data for MICVO monotherapy are expected in the first half of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.MICVO–KEYTRUDA combination-study updates are planned for the fourth quarter of 2026.

Negative

• Major point36,047,919 common shares issued at $2.90 per share dilute existing holders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Pre-funded warrants for 1,883,121 shares sold at $2.899 each add potential dilution.
• Minor point. Forward-looking: it has not happened yet and may not happen.Common warrants for 49,310,352 shares add potential dilution at a $3.50 exercise price, 21% above the offering price.
• Minor pointCommon warrant exercise requires stockholder approval and effectiveness of an amendment increasing authorized common shares.
• Minor point. Forward-looking: it has not happened yet and may not happen.Common warrants expire at the earlier of a five-year limit or a disclosure-linked 30-day deadline.
• Minor pointUnderwriting discounts, commissions and other offering expenses reduce proceeds available to Pyxis.

Argus 15 min delay 2 alerts

+0.37% vs previous close $2.20 last price 11.2x rel. volume Open Argus

Details

Market Reaction – PYXS

+2.7% Peak Tracked

$2.15 – $2.35 Day Range

$183.33M Market Cap

On Oct 2, the day this news came out, the latest delayed price for PYXS is 0.37% above the previous close. Argus tracked a peak move of +2.7% during the session. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $2.20. Relative volume is exceptionally heavy at 11.2x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Upfront gross proceeds: Approximately $110.0 million Common shares offered: 36,047,919 shares Pre-funded warrant shares: 1,883,121 shares +5 more

Upfront gross proceeds

Approximately $110.0 million

Before underwriting discounts, commissions, and other offering expenses

Common shares offered

36,047,919 shares

Public offering

Pre-funded warrant shares

1,883,121 shares

Issued in lieu of common stock to certain investors

Common warrant shares

49,310,352 shares

Aggregate shares purchasable under accompanying common warrants

Offering prices

$2.90 per share; $2.899 per pre-funded warrant

Public offering prices

Common warrant exercise price

$3.50 per share

Warrants are subject to the stated exercise conditions

Additional gross proceeds

Approximately $172.6 million

If all milestone-linked warrants are exercised in full for cash; before applicable expenses

Total gross proceeds

Approximately $282.6 million

Includes upfront proceeds and full cash exercise of milestone-linked warrants; before applicable expenses

Previous Offering Reports

2 past events · Latest: Sep 30

Same Type 2 events

1. Sep 30

   Offering pricing

   24h Move

   -19.8%

   Established final share and warrant quantities, upfront proceeds, exercise terms, and expected closing date.

2. Sep 29

   Offering proposal

   24h Move

   -19.8%

   Outlined share-or-warrant packages and conditional warrant exercise tied to shareholder approval.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, overall survival, antibody-drug conjugate, immunogenic cell death

4 terms

pre-funded warrants financial

"pre-funded warrants to purchase 1,883,121 shares of common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

overall survival medical

"public disclosure of overall survival data"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

antibody-drug conjugate medical

"a first-in-concept antibody-drug conjugate (ADC)"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

immunogenic cell death medical

"bystander effect and immunogenic cell death"

Immunogenic cell death is a form of cell death that not only kills diseased cells (such as cancer cells) but also releases signals that alert and activate the immune system to recognize and attack remaining disease. For investors, therapies that trigger this response can increase the chance of durable, long-lasting treatment effects—like sounding an alarm that recruits security guards—making such drugs potentially more valuable and differentiable in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously announced registered public offering (the "Offering") on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting discounts and commissions and other offering expenses. The Offering consisted of 36,047,919 shares of common stock at a public offering price of $2.90 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,883,121 shares of common stock at a public offering price of $2.899 per pre-funded warrant, in each case, accompanied by common warrants to purchase an aggregate of 49,310,352 shares of common stock.

The clinical milestone-linked common warrants are tied to Pyxis Oncology’s public disclosure of overall survival data (the “OS Data Release Date”) from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (“MICVO”) in second-line and beyond (“2L+”) recurrent/metastatic head and neck squamous cell carcinoma (“R/M HNSCC”), which is expected to occur in the first half of 2027. The warrants have an exercise price of $3.50 per common share, a 21% premium to the $2.90 public offering price. If all milestone-linked warrants are exercised in full for cash, the Offering would provide Pyxis Oncology with approximately $172.6 million in additional gross proceeds, for a total of approximately $282.6 million in gross proceeds, before deducting applicable expenses.

The common warrants will become exercisable only upon approval by the Company's stockholders of an amendment to the Company's certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the “Charter Amendment Effective Date”), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of (x) the Charter Amendment Effective Date and (y) the OS Data Release Date.

The Offering included participation from new and existing institutional investors, including OrbiMed, GordonMD Global Investments, BVF Partners, Coastlands Capital, and RTW Investments.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities acted as joint bookrunning managers for the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes. The Company also plans to disclose updated data from its ongoing Phase 1/2 combination dose escalation study of MICVO and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) for first-line (1L) R/M HNSCC patients in the fourth quarter of 2026.

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the Offering, including the anticipated total gross proceeds therefrom (including from any exercise of the common warrants); the Company's ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company's intended use of the net proceeds from the Offering; the Company's plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company's ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company's ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company's Phase 1 monotherapy study of MICVO; the timing and results from the Company's Phase 1/2 dose escalation study of MICVO and Merck’s anti-PD-1 therapy, KEYTRUDA^®; the risks inherent in drug research and development; the Company's projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company's reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company's ability to compete successfully against other drug candidates; and volatility in the price of the Company's common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled "Risk Factors" set forth in Part II, Item 1A of the Company's Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company's other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact:
IR@pyxisoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Pyxis Oncology raise in its October 2026 public offering?

Pyxis raised approximately $110.0 million in upfront gross proceeds, before underwriting discounts, commissions and other offering expenses. If all milestone-linked common warrants are exercised in full for cash, additional gross proceeds would be approximately $172.6 million, bringing total gross proceeds to approximately $282.6 million before applicable expenses.

When do the Pyxis Oncology milestone-linked common warrants expire?

The common warrants expire at the earlier of the fifth anniversary of the charter amendment’s effectiveness or the 30th calendar day after the later of that effective date and the overall survival data release date. The relevant data are from MICVO’s ongoing Phase 1 monotherapy study in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma.